{"schema_version":"secwatch.filing_event.v1","accession":"0001753926-24-001531","form_type":"8-K","ticker":"VANI","cik":"0001266806","company_name":"Vivani Medical, Inc.","filed_at":"2024-09-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.425549+00:00","generated_at":"2026-05-31T06:23:49.666696+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vivani Medical reports 82% sham-adjusted liver fat reduction with GLP-1 implant","bullets":["Sham-implant adjusted liver fat reduction of 82% in obese mouse model from single administration with twice-yearly dosing.","Previously reported 20% sham-implant adjusted weight loss, comparable to semaglutide arm.","Clinical development for NPM-115 program (exenatide implant) in overweight/obese patients on track for Q4 2024 start in Australia.","LIBERATE-1 first-in-human study expected to start Q4 2024 with data in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001753926-24-001531","json":"https://secwatch.observer/filing/0001753926-24-001531.json","markdown":"https://secwatch.observer/filing/0001753926-24-001531.md","text":"https://secwatch.observer/filing/0001753926-24-001531.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1266806/000175392624001531/0001753926-24-001531-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1266806/000175392624001531/vani-20240904.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T06:23:49.666696+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}